ViiV and the Medicines Patent Pool (MPP) signed a voluntary licensing agreement that will allow generic manufacturers in 90 countries to develop, manufacture and supply their own versions of Apretude, “subject to required regulatory approvals being obtained,” the partners announced on Thursday.